Steven Kanner, PhD, Caribou Biosciences, Berkeley, CA, discusses the management of adverse events (AEs) related to chimeric antigen receptor T-cell (CAR-T) therapies, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and graft versus host disease (GvHD). Dr Kanner first explains one method of eliminating the risk of GvHD by knocking out a component of the T-cell receptor and inserting a CAR at this site. Following this, Dr Kanner explains that other types of AEs are usually monitored during Phase I clinical trials and can often be treated with various approaches depending on their severity. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
